Advanced search

Co-delivery of nucleoside-modified mRNA and immunomodulators for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA

Rein Verbeke (UGent) , Ine Lentacker (UGent) , Laura Wayteck (UGent) , Karine Breckpot, Benedicte Descamps (UGent) , Christian Vanhove (UGent) , Stefaan De Smedt (UGent) and Heleen Dewitte (UGent)
Author
Organization

Citation

Please use this url to cite or link to this publication:

Chicago
Verbeke, Rein, Ine Lentacker, Laura Wayteck, Karine Breckpot, Benedicte Descamps, Christian Vanhove, Stefaan De Smedt, and Heleen Dewitte. 2017. “Co-delivery of Nucleoside-modified mRNA and Immunomodulators for Cancer Immunotherapy: Restoring the Immunogenicity of Immunosilent mRNA.” In mRNA Health, 5th International Conference, Abstracts.
APA
Verbeke, Rein, Lentacker, I., Wayteck, L., Breckpot, K., Descamps, B., Vanhove, C., De Smedt, S., et al. (2017). Co-delivery of nucleoside-modified mRNA and immunomodulators for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA. mRNA Health, 5th International conference, Abstracts. Presented at the 5th International mRNA Health conference.
Vancouver
1.
Verbeke R, Lentacker I, Wayteck L, Breckpot K, Descamps B, Vanhove C, et al. Co-delivery of nucleoside-modified mRNA and immunomodulators for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA. mRNA Health, 5th International conference, Abstracts. 2017.
MLA
Verbeke, Rein et al. “Co-delivery of Nucleoside-modified mRNA and Immunomodulators for Cancer Immunotherapy: Restoring the Immunogenicity of Immunosilent mRNA.” mRNA Health, 5th International Conference, Abstracts. 2017. Print.
@inproceedings{8611003,
  author       = {Verbeke, Rein and Lentacker, Ine and Wayteck, Laura and Breckpot, Karine and Descamps, Benedicte and Vanhove, Christian and De Smedt, Stefaan and Dewitte, Heleen},
  booktitle    = {mRNA Health, 5th International conference, Abstracts},
  language     = {eng},
  location     = {Berlin, Germany},
  title        = {Co-delivery of nucleoside-modified mRNA and immunomodulators for cancer immunotherapy: restoring the immunogenicity of immunosilent mRNA},
  year         = {2017},
}